BACKGROUND: : A growing body of evidence suggests that long-term survivors with 1 of the more common forms of adult cancer report a quality of life (QOL) similar to that in the general population. However, specific concerns have been identified (sexual dysfunction, fatigue, distress) in this population. Also, less is known concerning survivors of adult non-Hodgkin lymphoma (NHL), a disease often marked by alternating periods of disease and remission. Therefore, in the current study, the authors compared the QOL status of individuals who reported having active NHL with the QOL status of individuals who were disease-free short-term survivors (STS) (2-4 years postdiagnosis) and long-term survivors (LTS) (> or =5 years postdiagnosis). METHODS: Eligible survivors completed a mailed survey with validated measures, including physical and mental health status measured with the Medical Outcomes Study 36-item Short Form, cancer-related QOL, the Functional Assessment of Cancer Therapy-Lymphoma module, and self-reported impact of cancer. Other data were collected to examine as correlates. RESULTS: : Seven hundred sixty-one survivors identified from 2 North Carolina cancer registries participated. The average survivor was 10.4 years postdiagnosis (range, 2-44 years postdiagnosis) and was age 62.7 years (range, 25-92 years). Survivors with active disease (n = 109) demonstrated worse physical and mental health functioning, worse QOL, and less positive and more negative impacts of cancer compared with disease-free survivors (n = 652; all P < or = .01). No significant differences were observed between STS and LTS. CONCLUSIONS: Although survivors with NHL who had active disease reported more negative outcomes compared with off-treatment survivors, the length of time after diagnosis did not appear to matter with regard to outcomes for STS or LTS. In addition, mixed results from comparisons with general population norms suggested the need for supportive care for this diverse survivorship group.
BACKGROUND: : A growing body of evidence suggests that long-term survivors with 1 of the more common forms of adult cancer report a quality of life (QOL) similar to that in the general population. However, specific concerns have been identified (sexual dysfunction, fatigue, distress) in this population. Also, less is known concerning survivors of adult non-Hodgkin lymphoma (NHL), a disease often marked by alternating periods of disease and remission. Therefore, in the current study, the authors compared the QOL status of individuals who reported having active NHL with the QOL status of individuals who were disease-free short-term survivors (STS) (2-4 years postdiagnosis) and long-term survivors (LTS) (> or =5 years postdiagnosis). METHODS: Eligible survivors completed a mailed survey with validated measures, including physical and mental health status measured with the Medical Outcomes Study 36-item Short Form, cancer-related QOL, the Functional Assessment of Cancer Therapy-Lymphoma module, and self-reported impact of cancer. Other data were collected to examine as correlates. RESULTS: : Seven hundred sixty-one survivors identified from 2 North Carolina cancer registries participated. The average survivor was 10.4 years postdiagnosis (range, 2-44 years postdiagnosis) and was age 62.7 years (range, 25-92 years). Survivors with active disease (n = 109) demonstrated worse physical and mental health functioning, worse QOL, and less positive and more negative impacts of cancer compared with disease-free survivors (n = 652; all P < or = .01). No significant differences were observed between STS and LTS. CONCLUSIONS: Although survivors with NHL who had active disease reported more negative outcomes compared with off-treatment survivors, the length of time after diagnosis did not appear to matter with regard to outcomes for STS or LTS. In addition, mixed results from comparisons with general population norms suggested the need for supportive care for this diverse survivorship group.
Authors: A B Kornblith; J Anderson; D F Cella; S Tross; E Zuckerman; E Cherin; E Henderson; R B Weiss; M R Cooper; R T Silver Journal: Cancer Date: 1992-10-15 Impact factor: 6.860
Authors: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid L Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Jia Ruan; Peter Martin; Bijal Shah; Stephen J Schuster; Sonali M Smith; Richard R Furman; Paul Christos; Amelyn Rodriguez; Jakub Svoboda; Jessica Lewis; Orel Katz; Morton Coleman; John P Leonard Journal: N Engl J Med Date: 2015-11-05 Impact factor: 91.245
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941
Authors: Geraldine Leung; Christina Baggott; Claudia West; Charles Elboim; Steven M Paul; Bruce A Cooper; Gary Abrams; Anand Dhruva; Brian L Schmidt; Kord Kober; John D Merriman; Heather Leutwyler; John Neuhaus; Dale Langford; Betty J Smoot; Bradley E Aouizerat; Christine Miaskowski Journal: Lymphat Res Biol Date: 2014-02-06 Impact factor: 2.589
Authors: Kimberly Stephens; Bruce A Cooper; Claudia West; Steven M Paul; Christina R Baggott; John D Merriman; Anand Dhruva; Kord M Kober; Dale J Langford; Heather Leutwyler; Judith A Luce; Brian L Schmidt; Gary M Abrams; Charles Elboim; Deborah Hamolsky; Jon D Levine; Christine Miaskowski; Bradley E Aouizerat Journal: J Pain Date: 2013-10-12 Impact factor: 5.820
Authors: Shing Fung Lee; Miguel Angel Luque-Fernandez; Yu Hui Chen; Paul J Catalano; Chi Leung Chiang; Eric Yuk-Fai Wan; Ian Chi-Kei Wong; Ming Hui Chen; Andrea K Ng Journal: Blood Adv Date: 2020-10-27